会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明授权
    • Serotonin 5-HT1A and dopamin D2 receptor ligands
    • 5-羟色胺5-HT1A和多巴胺D2受体配体
    • US06514993B1
    • 2003-02-04
    • US09424930
    • 1996-12-09
    • Jens Kristian PerregaardEjner Knud Moltzen
    • Jens Kristian PerregaardEjner Knud Moltzen
    • A61K314439
    • C07D401/06C07D233/32C07D233/36
    • The present invention relates to a novel series of 4-phenylpiperazines, 4-phenylpiperidines and 4-phenyl-1,2,3,6-tetrahydropyridines compounds of general formula (I) wherein A is alkylene, alkenylene, alkynylene, and C3-7 cycloalkylene; R1 is a C3-10 alkyl, alkenyl, or alkynyl group, cycloalk(en)yl, cycloalk(en)yl-alk(en/yn)yl, trifluoromethylsulfonyl, or alkylsulfonyl, R2-R5 are optional substituents; R9 and R10 are hydrogen, alkyl or together form an ethylene or propylene bridge; W is O or S; V is O, S, CR6R7, or NR8 wherein R6, R7, and R8 are hydrogen or alkyl, alkenyl, cycloalkyl, cycloalkylalkyl, optionally substituted arylalkyl or aryl, or R6 and R7 constitute a 3-7 membered spiro ring; Z is —(CH2)m—, m being 2 or 3 or Z is —CH═CH—; X is N, C or CH; show effects on central serotonin 5-HT1A and dopamine D2 receptors. Thus the novel compounds are useful in the treatment of certain psychic and neurologic disorders, in particular psychosis.
    • 本发明涉及通式(I)的新一系列4-苯基哌嗪,4-苯基哌啶和4-苯基-1,2,3,6-四氢吡啶化合物,其中A是亚烷基,亚烯基,亚炔基和C3-7 亚环烷基 R 1是C 3-10烷基,烯基或炔基,环烷基(烯)基,环烷基(烯)基 - 烯(烯/炔)基,三氟甲磺酰基或烷基磺酰基,R 2 -R 5是任选的取代基; R9和R10是氢,烷基或一起形成乙烯或丙烯桥; W为O或S; V是O,S,CR 6 R 7或NR 8,其中R 6,R 7和R 8是氢或烷基,烯基,环烷基,环烷基烷基,任选取代的芳烷基或芳基,或R 6和R 7构成3-7元螺环; Z是 - (CH 2)m - ,m是2或3或Z是-CH = CH-; X为N,C或CH; 显示对中枢5-羟色胺5-HT1A和多巴胺D2受体的影响。 因此,新化合物可用于治疗某些精神病和神经障碍,特别是精神病。
    • 5. 再颁专利
    • 1,2,3-triazole and tetrazole substituted piperidine or
tetrahydropyridine compounds useful as acetylcholine agonists
    • USRE36374E
    • 1999-11-02
    • US648240
    • 1996-05-13
    • Klaus Peter BogesoKlaus GundertofteEjner Knud MoltzenHenrik Pedersen
    • Klaus Peter BogesoKlaus GundertofteEjner Knud MoltzenHenrik Pedersen
    • A61K31/4427A61K31/445A61P21/00A61P25/02A61P25/28C07D401/04C07D413/04C07D417/04
    • C07D401/04C07D413/04C07D417/04
    • The present invention relates to novel compounds of the following formula, where the dotted line designates in optional bond: ##STR1## wherein "het" designates a five membered heterocyclic ring which may include 1 or 2 double bonds and 1-4 heteroatoms selected from nitrogen, oxygen or sulphur, provided that "het" may not designate a 1,4- or 1,3,4-oxadiazole,R.sup.1 is selected from hydrogen, lower alkyl, optionally substituted with phenyl which may be substituted with halogen, lower alkyl, or lower alkoxy, or a group R.sup.6 --CO--NH--CH.sub.2 -- or R.sup.6 --O--CO--, wherein R.sup.6 is lower alkyl, branched or unbranched, or phenyl optionally substituted with halogen, trifuoromethyl, lower alkyl, hydroxy, lower alkoxy, or lower acyloxy;R.sup.2 and R.sup.3 are the same or different, each representing hydrogen, lower alkyl, cycloalkyl (3-6 C-atoms), lower alkenyl, lower alkadienyl, lower alkynyl, optionally substituted with hydroxy, halogen or phenyl, in which the phenyl group may be substituted with halogen, trifluoromethyl, lower alkyl, hydroxy or lower alkoxy; R.sup.2 and R.sup.3 may further, respectively, be selected from trifluoromethyl or phenyl optionally substituted with halogen, trifluoromethyl, lower alkyl, hydroxy, lower alkoxy or lower acyloxy, or R.sup.2 and R.sup.3 may, respectively, be a group OR.sup.7 or SR.sup.7 wherein R.sup.7 is defined as R.sup.2 or R.sup.3, andif "het" includes 2 or more carbon atoms R.sup.4 and R.sup.5 are the same or different, and each is defined as R.sup.2 or R.sup.3, and if "het" includes only one carbon atom, there is only one substituent, R.sup.4, on the heterocyclic ring, and R.sup.4 is defined as R.sup.2 or R.sup.3,as well as individual stereo isomers and pharmaceutically acceptable acid addition salts thereof.The invention moreover relates to methods for the preparation of the compounds of formula 1, to novel intermediates, to pharmaceutical compositions containing same and to methods for the treatment of disorders, caused by malfunction of the acetylcholine (AcCh) or muscarinic system, by administering a non-toxic effective amount of a compound of formula I.